Which Peptides Are FDA-Approved? (Full List)

If you’ve read that a peptide is “FDA-approved,” it’s worth slowing down, because the phrase is used loosely online and it almost never means what people assume. A surprising number of the peptides discussed in gyms, clinics, and forums — BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu — have never been approved by the FDA for anything. At the same time, several peptide drugs you may not even think of as “peptides” are fully approved and sold at every pharmacy in the country. This page lays out which is which, as of mid-2026.

What “FDA-approved” actually means

FDA approval is not a label that attaches to a molecule in the abstract. It attaches to a specific product, made to pharmaceutical manufacturing standards, at a defined dose, for a defined medical condition, after that product has gone through preclinical work and human clinical trials and survived FDA review of a New Drug Application or Biologics License Application.

That has two consequences people routinely miss. First, the same chemical can be approved under one brand for one use and completely unapproved for everything else — bremelanotide is approved for one narrow condition in women, but that doesn’t make every use of it “FDA-approved.” Second, a peptide that has simply never been put through that process isn’t “rejected” or “banned” by default; it’s just unapproved, which is a different status with its own legal consequences.

Note: “FDA-approved,” “legal to compound,” and “sold as research-use-only” are three different statuses. A peptide can sit in any one of them, and the popular ones are mostly not in the first. Approval status and how you can legally access something are related but separate questions, covered in our legal status guide.

The peptides that are FDA-approved

Quite a few peptide-based drugs have full approval — by some counts over eighty across decades of medicine. Most aren’t marketed as “peptide therapy” because they’re simply established prescription drugs. Here are the ones most relevant to the audience searching for peptides.

GLP-1 weight-loss and diabetes medicines

These are by far the most-used approved peptides in the US, even though they’re rarely filed under “peptides” in casual conversation.

• Semaglutide — approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management), with a cardiovascular-risk label as well. A GLP-1 receptor agonist.
• Tirzepatide — approved as Mounjaro (type 2 diabetes) and Zepbound (weight management, and more recently obstructive sleep apnea in adults with obesity). A dual GIP/GLP-1 agonist.
• Liraglutide — the earlier daily GLP-1, approved as Victoza (diabetes) and Saxenda (weight management).

These are genuine, trial-backed, pharmacy-stocked approvals. If you want the practical side — pricing, brands, and how the recent compounding changes affect them — see the weight-loss cluster.

Tesamorelin (Egrifta)

Tesamorelin is the only FDA-approved growth-hormone-releasing hormone analog still on the market. It’s approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. It belongs to the same broad family as sermorelin and CJC-1295 in that it nudges the pituitary to release growth hormone — but its approval is narrow, and using it for general anti-aging or body composition is off-label, not an approved use.

Bremelanotide (Vyleesi) — i.e. “PT-141”

The molecule sold in research circles as PT-141 is approved as bremelanotide (Vyleesi), cleared in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It’s a melanocortin-receptor agonist, structurally related to melanotan II, but unlike melanotan II it went through the approval process for one defined indication. Anything outside that — men, other situations — is off-label use of an approved drug.

Afamelanotide (Scenesse)

Afamelanotide is an α-melanocyte-stimulating hormone analog approved to increase pain-free light exposure in adults with erythropoietic protoporphyria, a rare condition causing severe sunlight sensitivity. It’s a useful example of how specific approvals are: it is not a tanning or cosmetic product despite being in the melanocortin family.

Older, established peptide drug classes

Several long-standing hospital and specialty drugs are peptides, which is why “peptide medicine” isn’t new:

• GnRH agonists/antagonists — leuprolide (Lupron), goserelin (Zoladex), triptorelin, histrelin, degarelix (Firmagon), used in prostate cancer, endometriosis, and related conditions.
• Somatostatin analogs — octreotide (Sandostatin), lanreotide (Somatuline), pasireotide (Signifor), used for acromegaly and certain tumors.
• Mecasermin (Increlex) — an IGF-1 product for severe IGF-1 deficiency.

You won’t see these advertised by wellness clinics, but they matter to the question because they show that “FDA-approved peptide” describes a real, established list — it’s just not the list most people are picturing.

The sermorelin wrinkle

Sermorelin deserves a special mention. It was approved years ago (as Geref) as a diagnostic agent, then voluntarily withdrawn from the market by its manufacturer for commercial reasons — not safety. Because it once held approval, it sits in a stronger legal position than peptides that were never approved, and it remains available through compounding. So “sermorelin” is neither a current marketed approved drug nor a never-approved research peptide; it’s a third thing, which is exactly why these categories are worth getting precise about.

The peptides that are not FDA-approved

This is where most of the popular search terms land. None of the following are FDA-approved for human use:

• BPC-157 — never submitted for approval; no approved indication.
• TB-500 (thymosin beta-4 fragment) — not approved.
• CJC-1295 — not approved; in fact it’s treated as a developmental compound and remains off-limits for human use.
• Ipamorelin, GHK-Cu, MOTS-C, AOD-9604, selank, semax, melanotan II, epitalon, thymosin alpha-1 — none approved as a finished drug for general human use.
• Cagrilintide and retatrutide — these are real pharmaceutical-pipeline molecules in clinical trials, but as of mid-2026 they are not yet approved. Being in Phase 3 is not the same as being approved.

“Not approved” doesn’t tell you whether something is dangerous, useless, or promising — only that it hasn’t cleared the trials-and-review bar. The evidence behind these compounds ranges from genuinely interesting early research to almost nothing in humans. What it does tell you is that there’s no FDA-vetted dose, purity standard, or labeled use behind them.

The in-between: compounding and the 2026 changes

Between “approved” and “research chemical” sits compounding — licensed pharmacies preparing a medicine for an individual patient with a prescription. A peptide can be unapproved as a finished drug yet still, in principle, be eligible for compounding if it satisfies the FDA’s rules for bulk substances.

This is the area that changed in 2026, and it’s easy to overstate. In April 2026 the FDA removed a group of peptides — including BPC-157 and TB-500 — from the restricted “Category 2” list. That removal stripped the explicit “significant safety risks” designation, but it did not approve those peptides and did not by itself authorize compounding. The next step is a Pharmacy Compounding Advisory Committee review scheduled for July 23–24, 2026, which will consider whether a first batch of peptides should be added to the authorized 503A bulks list. Even a favorable recommendation there is non-binding and would still need formal rulemaking to take effect. In short: the door is being looked at, not opened, and CJC-1295 in particular is not part of that reopening.

We keep the deep mechanics out of this page on purpose. For the timeline and what it means, see the 2026 reclassification explainer; for how 503A and 503B pharmacies actually differ, see 503A vs 503B.

”Research-use-only” peptides

The third bucket is the one to be most careful with. Many peptides are sold online labeled “for research use only — not for human consumption.” That label is not a loophole; it’s a statement that the product is not a medicine, has not been made to drug-manufacturing standards, and is not intended to go into a person. These products carry no approval, no guaranteed purity or identity, and no clinical oversight. We cover what that label means, and the real risks, in research peptides explained.

How to tell which bucket a peptide is in

A quick way to place any peptide you come across:

1. Does it have a brand name and an FDA-approved indication? (e.g., Wegovy, Egrifta, Vyleesi) → it’s approved, at least for that use.
2. Is it being prepared by a licensed pharmacy for you specifically with a prescription? → it’s a compounded medicine, whose permissibility depends on the current bulk-substance rules.
3. Is it sold as a product labeled “research use only”? → it’s an unapproved research chemical, not a medicine.

If a website blurs these — calling a research-use-only product “FDA-approved,” or implying that being removed from Category 2 means a peptide is now approved — treat that as a red flag about the source. Getting the category right is the foundation for every other decision, including how (and whether) you can access something legally.

This page is educational and reflects US regulatory status as of June 2026; approval and compounding rules in this area are changing quickly, so check the dated reclassification page for the latest before relying on any specific status.